Navigation Links
Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
Date:9/24/2010

TAMPA, Fla. Moffitt Cancer Center and GLG Pharma, LLC announced today that they have entered into a licensing agreement under which GLG Pharma, LLC has acquired the exclusive worldwide rights to a technology platform that includes a series of STAT3 inhibitors. Researchers at Moffitt discovered several classes of STAT3 inhibitors and evaluated their potential pre-clinically as novel anti-cancer drugs.

"Persistently activated STAT3 is a major contributor to human cancer; validating its usefulness as a cancer therapeutic target in collaboration with GLG will be a major milestone," said Said Sebti, Ph.D., chair of the Drug Discovery Department at Moffitt.

"One of several recent startup companies to be based on Moffitt technologies, GLG brings a highly experienced management team to the mix," said Ray Carpenter, senior licensing manager of The Office of Technology Management and Commercialization at Moffitt. "Their combined experience in taking technologies through clinical trials instills confidence that these technologies surrounding an important target, like the STAT3 pathway, is being placed in capable hands. Our office is delighted that GLG Pharma will move this technology from the laboratory to the clinic to improve patient care."

Under the license agreement, GLG Pharma has agreed to pay Moffitt when various commercialization milestones are reached, as well as make royalty payments on the sales of testing services and licensed products.

"This license agreement is the first key milestone established for the company in 2010," said Hector J. Gomez, M.D., Ph.D., CEO of GLG Pharma. "We believe that STAT3 inhibitors are the next generation of targeted therapies. They are anticipated to be very specific, have a broad spectrum of activity and are expected to be well tolerated and more efficacious compounds than current therapies."


'/>"/>

Contact: Michelle Foley
MFoley@Moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Cancer-associated long noncoding RNA regulates pre-mRNA splicing
3. Declining breast cancer incidence in Canada with declining HRT usage
4. Sexual Problems May Arise After Breast Cancer
5. UCLA cancer researchers discover new signaling pathway that controls cell development and cancer
6. Patients with cancer who stop hospice care boost health-care costs
7. Mammograms Cut Breast Cancer Death Rates, But Only Modestly: Study
8. David Cheresh receives top award for cancer metastasis research
9. 70 percent of women likely to experience sexual problems after breast cancer
10. Physical limitations of breast cancer survivors
11. Synthetic lethality strategy improves molecularly targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family owned insurance company ... launching a cooperative charity drive with the Tarrant Area Food Bank in the hopes ... and families in need, the Tarrant County Food Bank offers hope and security to ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces ... The print component of “Revolutionizing Cancer Care” is distributed within the February 12 ... Seattle, with a circulation of approximately 250,000 copies and an estimated readership of ...
(Date:2/12/2016)... ... February 12, 2016 , ... US Sport Camps is pleased to announce the ... in Norwalk, serves as the host site and directing the camps is PGA Professional ... had successful camps in recent years around Des Moines and are fortunate to have ...
(Date:2/12/2016)... ... 12, 2016 , ... The aging population and longer life ... care. With that, says Patrick Loughney, president of Longtree & Associates, LLC ... term care environments. His company, which offers prep courses and workshops in long ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
Breaking Medicine Technology: